Jerry Thomas

Title: Jerry Thomas: Innovator in Activatable Binding Polypeptides

Introduction

Jerry Thomas is a prominent inventor based in Goleta, California, known for his significant contributions to the field of biotechnology. He holds a total of seven patents, showcasing his innovative approach to developing activatable binding polypeptides.

Latest Patents

Among his latest patents is the invention of activatable anti-VEGF scFv. This patent describes activatable binding polypeptides (ABPs) that include a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The ABPs are designed to exhibit an 'activatable' conformation, making at least one of the TBMs less accessible to the target when uncleaved, compared to after the cleavage of the CM in the presence of a cleaving agent. Additionally, the patent provides libraries of candidate ABPs, methods for screening to identify such ABPs, and various methods of use. Another notable patent focuses on methods for manufacturing ABPs that comprise matrix metalloprotease cleavable moieties, further emphasizing his expertise in this innovative area.

Career Highlights

Jerry Thomas has had a distinguished career, working with reputable organizations such as the University of California and Cytomx Therapeutics, Inc. His work has significantly advanced the understanding and application of activatable binding polypeptides in therapeutic contexts.

Collaborations

Throughout his career, Jerry has collaborated with notable colleagues, including Patrick Sean Daugherty and Nancy E. Stagliano. These collaborations have contributed to the development of innovative solutions in the field of biotechnology.

Conclusion

Jerry Thomas is a key figure in the development of activatable binding polypeptides, with a strong patent portfolio and a history of impactful collaborations. His work continues to influence advancements in biotechnology and therapeutic applications.